| Schedule of financial information by reportable segment |
The following is financial information relating to the operating segments (in thousands): | | | | | | | | | | For the Year Ended June 30, 2026 | | | | Protein Sciences | | | Diagnostics and Spatial Biology | | | Total | Net sales | | $ | 874,620 | | $ | 336,365 | | $ | 1,210,985 | Other revenue(1) | | | | | | | | | 5,439 | Intersegment | | | | | | | | | (1,385) | Consolidated net sales | | | | | | | | $ | 1,215,039 | Segment operating income | | | | | | | | | | Cost of sales | | | 218,837 | | | 150,553 | | | | Selling, general and administrative | | | 238,994 | | | 111,794 | | | | Research and development | | | 57,388 | | | 36,320 | | | | Segment operating income | | $ | 359,401 | | $ | 37,698 | | $ | 397,099 | Unallocated amounts | | | | | | | | | | Amortization of intangibles | | | | | | | | | (61,181) | Acquisition related expenses and other | | | | | | | | | (7,986) | Certain litigation charges | | | | | | | | | (5,513) | Stock based compensation, inclusive of employer taxes | | | | | | | | | (42,637) | Restructuring and restructuring-related costs | | | | | | | | | (21,059) | Recovery of assets held-for-sale | | | | | | | | | 6,789 | Corporate general, selling, and administrative expenses | | | | | | | | | (11,049) | Impact of business held-for-sale(1) | | | | | | | | | (2,573) | Consolidated operating income | | | | | | | | $ | 251,890 |
| (1) | Since June 30, 2025, the Company has had a business that has met the held-for-sale criteria. Segment results exclude the results of this business held-for-sale for fiscal 2026. |
| | | | | | | | | | For the Year Ended June 30, 2025 | | | | Protein Sciences | | | Diagnostics and Spatial Biology | | | Total | Net sales | | $ | 870,245 | | $ | 346,263 | | $ | 1,216,508 | Other revenue(1) | | | | | | | | | 4,152 | Intersegment | | | | | | | | | (1,025) | Consolidated net sales | | | | | | | | $ | 1,219,635 | Segment operating income | | | | | | | | | | Cost of sales | | | 212,225 | | | 147,946 | | | | Selling, general and administrative | | | 229,058 | | | 136,103 | | | | Research and development | | | 58,609 | | | 40,890 | | | | Segment operating income | | $ | 370,353 | | $ | 21,324 | | $ | 391,677 | Unallocated amounts | | | | | | | | | | Costs recognized on sale of acquired inventory | | | | | | | | | (751) | Amortization of intangibles | | | | | | | | | (75,321) | Acquisition related expenses and other | | | | | | | | | (12,064) | Certain litigation charges | | | | | | | | | (41,827) | Stock based compensation, inclusive of employer taxes | | | | | | | | | (42,158) | Restructuring and restructuring-related costs | | | | | | | | | (28,231) | Impairment of assets held-for-sale | | | | | | | | | (80,503) | Corporate general, selling, and administrative expenses | | | | | | | | | (8,088) | Impact of business held-for-sale(1) | | | | | | | | | (479) | Consolidated operating income | | | | | | | | $ | 102,255 |
| (1) | Since December 31, 2023, the Company has had a business that has met the held-for-sale criteria. Segment results exclude the results of this business held-for-sale for fiscal 2025 |
| | | | | | | | | | For the Year Ended June 30, 2024 | | | | Protein Sciences | | | Diagnostics and Spatial Biology | | | Total | Net sales | | $ | 830,902 | | $ | 326,392 | | $ | 1,157,294 | Other revenue(1) | | | | | | | | | 4,153 | Intersegment | | | | | | | | | (2,387) | Consolidated net sales | | | | | | | | $ | 1,159,060 | Segment operating income | | | | | | | | | | Cost of sales | | | 201,981 | | | 134,963 | | | | Selling, general and administrative | | | 217,235 | | | 127,131 | | | | Research and development | | | 56,911 | | | 39,752 | | | | Segment operating income | | $ | 354,775 | | $ | 24,546 | | $ | 379,321 | Unallocated amounts | | | | | | | | | | Costs recognized on sale of acquired inventory | | | | | | | | | (729) | Amortization of intangibles | | | | | | | | | (78,318) | Acquisition related expenses and other | | | | | | | | | (6,980) | Certain litigation charges | | | | | | | | | (3,506) | Impairment of assets held-for-sale | | | | | | | | | (21,963) | Stock based compensation, inclusive of employer taxes | | | | | | | | | (40,277) | Restructuring and restructuring-related costs | | | | | | | | | (12,245) | Corporate general, selling, and administrative expenses | | | | | | | | | (9,142) | Impact of business held-for-sale(1) | | | | | | | | | 525 | Consolidated operating income | | | | | | | | $ | 206,686 |
| (1) | Since December 31, 2023, the Company has had a business that has met the held-for-sale criteria. Segment results exclude the six-month results of this business held-for-sale for the period starting December 31, 2023 through June 30, 2024 while the business has met the held-for-sale criteria. |
The Company considers consumables sold in the Protein Sciences and Diagnostics and Spatial Biology segments to represent different groups of products and therefore have separately disclosed the related consumables revenue (in thousands): | | | | | | | | | | | | Year Ended June 30, | | | 2026 | | 2025 | | 2024 | Consumables revenue - Protein Sciences | | $ | 680,848 | | $ | 684,165 | | $ | 657,679 | Consumables revenue - Diagnostics and Spatial Biology | | | 304,267 | | | 283,969 | | | 266,348 | Consumables revenue - Other revenue(1) | | | — | | | 4,152 | | | 4,153 | Total consumable revenue | | $ | 985,115 | | $ | 972,286 | | $ | 928,180 |
| (1) | Includes the results of a business that has met the held-for-sale criteria since December 31, 2023. |
|